Liang Wang

28PUBLICATIONS
85CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Oct 12, 2026
CUE domain-containing 2 promotes diffuse large B-cell lymphoma progression via PP2A-B55β degradation and shapes macrophage-mediated immune responses.

|Aug 11, 2026
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study.

|Jul 08, 2026
Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy.

|Jun 15, 2026
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.

|Jun 15, 2026
Immune-Mediated IgA Nephropathy Induced by PD-1 Blockade in Extranodal NK/T-Cell Lymphoma.

|Jun 06, 2026
Association of baseline immune cell composition with CAR-T cell expansion and survival in Relapsed/Refractory large B-Cell lymphoma.

Pageof 5

Frequent Collaborators

3 joint publications

Xiaojie Liang

3 joint publications

WeiXiang Lu

2 joint publications

Lin Bai

2 joint publications

Shengyu Tian